Tag Archive for: Eli Lilly

Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly’s own treatment Mounjaro leads to faster and greater weight loss.

Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.

Eli Lilly will acquire Morphic Holding for $3.2 billion in cash, the companies said on Monday, giving the U.S. drugmaker access to an experimental drug for types of inflammatory bowel diseases.

Donanemab, which will be marketed as Kisunla, will compete with Biogen and Eisai’s Leqembi.

“Despite gaining approval nearly a year ago, uptake of Leqembi has been slow. While the approval of Kisunla will provide further confidence in the anti-Aβ mAbs, which could help drive the uptake of both drugs, many of the challenges faced by Leqembi will also apply to Kisunla,” says Philippa Salter, managing neurology analyst at GlobalData.

U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk and Eli Lilly to reduce the prices of their weight loss and diabetes drugs, in an opinion piece by them published in USA Today on Tuesday.

The company unveiled detailed findings from the Phase III SURMOUNT-OSA program, showing that its blockbuster weight-loss drug Zepbound (tirzepatide) could significantly improve disease severity in patients with moderate-to-severe obstructive sleep apnea and obesity.

Eli Lilly on Thursday announced it has filed additional lawsuits against medical spas, wellness centers and other similar entities, which allegedly have been selling unapproved compounded versions of the pharma’s best-selling GLP-1 receptor agonist tirzepatide.

Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s treatment donanemab outweighed its risks, and agreed that trial data showed it was effective in patients with an early stage of the memory-robbing disease.

The drug is a potential rival to Eisai and Biogen’s Leqembi, which won approval last July.